Marion Pons , Stylianos Georgiadis , Mikkel Østergaard , Zohra Faizy Ahmadzay , Bente Glintborg , Jette Heberg , Sara Nysom Christensen , Simon Rasmussen , Anne Gitte Loft , Isabel Castrejón , Fernando Sánchez-Alonso , Florenzo Iannone , Dan Nordström , Anna-Mari Hokkanen , Adrian Ciurea , Michael J. Nissen , Jakub Závada , Karel Pavelka , Ziga Rotar , Katja Perdan Pirkmajer , Lykke Midtbøll Ørnbjerg
{"title":"Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis","authors":"Marion Pons , Stylianos Georgiadis , Mikkel Østergaard , Zohra Faizy Ahmadzay , Bente Glintborg , Jette Heberg , Sara Nysom Christensen , Simon Rasmussen , Anne Gitte Loft , Isabel Castrejón , Fernando Sánchez-Alonso , Florenzo Iannone , Dan Nordström , Anna-Mari Hokkanen , Adrian Ciurea , Michael J. Nissen , Jakub Závada , Karel Pavelka , Ziga Rotar , Katja Perdan Pirkmajer , Lykke Midtbøll Ørnbjerg","doi":"10.1016/j.jbspin.2024.105824","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months.</div></div><div><h3>Patients and methods</h3><div>Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥<!--> <!-->2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses.</div></div><div><h3>Results</h3><div>The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with<!--> <!-->≥<!--> <!-->2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with<!--> <!-->≥ <!--> <!-->2 prior b/tsDMARDs at 24 months in axSpA and PsA.</div></div><div><h3>Conclusion</h3><div>This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 3","pages":"Article 105824"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Joint Bone Spine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297319X24001350","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months.
Patients and methods
Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses.
Results
The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with ≥ 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with ≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA.
Conclusion
This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.
期刊介绍:
Bimonthly e-only international journal, Joint Bone Spine publishes in English original research articles and all the latest advances that deal with disorders affecting the joints, bones, and spine and, more generally, the entire field of rheumatology.
All submitted manuscripts to the journal are subjected to rigorous peer review by international experts: under no circumstances does the journal guarantee publication before the editorial board makes its final decision. (Surgical techniques and work focusing specifically on orthopedic surgery are not within the scope of the journal.)Joint Bone Spine is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.